Nurix Therapeutics secures $700M upfront from Roche in BTK degrader deal

Roche is paying $700 million upfront to co-develop Nurix Therapeutics' BTK degrader bexobrutideg, a deal that validates targeted protein degradation as a potential challenger to the $19 billion BTK inhibitor market.

"The addition of bexobrutideg complements Roche's existing strengths in hematology and provides a cross-therapeutic opportunity to extend the pipeline's reach in immunology and neurology," Levi Garraway, Roche's chief medical officer and head of global product development, said.

Nurix will receive an upfront cash payment of $700 million and is eligible for development, regulatory and sales milestones that could bring total deal value to $2.3 billion. Development costs will be split 40% by Nurix and 60% by Roche, with the two companies sharing U.S. profits and losses equally. Outside the United States, Roche will handle commercialization, with Nurix receiving royalties in the low- to high-teens.

The deal positions bexobrutideg — an oral, brain-penetrant BTK degrader — against a class of drugs projected to generate $19 billion in annual sales by 2031, according to Clarivate. Unlike conventional BTK inhibitors that only block kinase activity, bexobrutideg eliminates the entire BTK protein, potentially overcoming resistance mutations that limit current therapies. The companies plan to initiate a Phase 3 trial in second-line chronic lymphocytic leukemia in summer 2026 and expand into Phase 2 studies in multiple sclerosis and chronic spontaneous urticaria.

How Degradation Differs From Inhibition

BTK is a central signaling node controlling B-cell growth and immunologic activity. Current standard-of-care BTK inhibitors, including AbbVie's Imbruvica and AstraZeneca's Calquence, block the enzyme's kinase function but leave the protein's scaffolding role intact. Bexobrutideg harnesses the body's natural protein disposal system to eliminate BTK entirely, removing both functions and potentially addressing acquired resistance mutations that drive disease progression in CLL.

The CLL market alone is forecast to grow to $16 billion by 2035 from $12 billion in 2024, according to Decision Resources Group. The combined non-Hodgkin lymphoma and CLL market is projected to reach $41 billion by 2031, with BTK-targeting therapies remaining the leading class at approximately $19 billion.

Expansion Beyond Oncology

Roche and Nurix plan to explore bexobrutideg in immunology and neurology, where BTK also plays a role in disease pathology. Chronic spontaneous urticaria, a debilitating skin condition characterized by recurring hives, and multiple sclerosis, which affects nearly 3 million people worldwide, represent new addressable markets for the BTK degrader mechanism. The brain-penetrant property of bexobrutideg is particularly relevant for MS, where the blood-brain barrier limits many existing therapies.

Investment Implications

For Nurix, the deal provides substantial non-dilutive capital and validation of its targeted protein degradation platform. The Brisbane, California-based company's $700 million upfront payment significantly extends its cash runway. Roche gains a potential best-in-class asset in a therapeutic area where it already holds a strong portfolio of B-cell malignancy drugs, including Columvi and Lunsumio.

"We believe Roche is the ideal partner to help translate the promise of targeted protein degradation into meaningful impact for patients worldwide," Arthur T. Sands, president and chief executive officer of Nurix Therapeutics, said. "As a single agent, bexobrutideg has shown highly promising results in B-cell malignancy clinical trials to date."

The transaction is expected to close in the third quarter of 2026, subject to customary conditions including antitrust review under the Hart-Scott-Rodino Act.

This article is for informational purposes only and does not constitute investment advice.